Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
about
Estrogenic control of mitochondrial function and biogenesisLoss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancerThresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009Tamoxifen Resistance: Emerging Molecular TargetsMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItRoles for miRNAs in endocrine resistance in breast cancerPhosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerEpigenetic regulation in estrogen receptor positive breast cancer--role in treatment responseResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancersApplication of computational approaches to study signalling networks of nuclear and Tyrosine kinase receptorsInverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.Tailored targeted therapy for all: a realistic and worthwhile objective?Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatmeResponsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells.Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinibEGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expressionOptimizing the use of neoadjuvant endocrine therapy.Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells.Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells.Function of RasGRP3 in the formation and progression of human breast cancerHITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancerCircadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.Endocrine Treatment - 'Old-Fashioned' Therapy Becoming Redundant in an Era of Molecular Medicine?Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast CancerEstrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer.PPARα in Obesity: Sex Difference and Estrogen Involvement.Dynamic modelling of oestrogen signalling and cell fate in breast cancer cellsDevelopment of subtype-selective oestrogen receptor-based therapeutics.
P2860
Q24651145-D30E0886-9C54-4D63-BC81-3D9896A1161FQ24653934-08FD54D8-1149-44E6-BA6F-8D6E65F2AC32Q24657145-803994BC-24DC-436B-BF0D-B6A153A48F2AQ26739969-CE5E0266-568D-432F-8B99-C9D01166B17EQ26752780-F2542119-8B74-45FC-B5C9-C9273DAD201CQ26783076-48B52708-AE6C-438B-87FB-5A00472BC6A4Q26862550-C47331A8-06B9-47C8-99E2-A14C20EEAAA2Q27001260-C7CB8965-701E-49E5-AB72-27EE4F1A9954Q27694612-BFDA0F91-1E06-4522-932E-FEED5DE27E15Q28072897-82F40C16-F543-4A08-A9DF-CC0EC2FEC70AQ28084982-C4BB317F-1CCF-42D2-9950-5C4950AA278DQ28728499-15F0789D-6E21-41AB-A75E-CBB38FE2AC82Q30497156-095CDA73-6737-4F15-BD78-BB1839C5EBBBQ31134061-79171FAF-CF14-4A7F-8C40-E82FC3B2D257Q33555473-89847916-7C05-478E-8B7E-140B1C3F9021Q33561588-BDFEDDF2-A3ED-4916-805A-8D9F1EFB3FC5Q33592917-5543386A-2C5E-4470-B6F4-A58D263EECEDQ33664216-158F905B-501B-484C-932A-C66C9A6BCBC9Q33700933-B873C56B-F5A5-4189-9DF4-B45B3C6BDE04Q33723383-EDBA92A6-ED00-4696-B5A8-30D60211F15BQ33739267-67FCAEC7-47F4-4EA4-B7A9-7B67663D798BQ33743983-9A7B60D8-19ED-4380-95E3-75A4E46D8E11Q33760654-1BDBFEC7-475E-41C6-92B5-D28BFDBEBD07Q33793142-C167B8F0-4C15-4C1E-959F-5F7DA2128284Q33794923-6FA76B7D-D2B9-4AD3-91C9-0F765D399DC9Q33829405-CF8A509D-1BB5-4346-9B6B-4E866A4F7129Q33925038-37B1BB40-B264-4B9D-8F5F-46B758A49D6EQ33945493-5700C644-6C41-442A-959D-2A3C2BC2129CQ33954542-FF9793CA-4ACD-4CAE-9470-38EFE0297638Q33960160-AB18597F-40CA-4AB5-B535-3A96ABD699B1Q33970563-3E3E5665-D0CE-4506-82E1-01C4C2B26DD8Q33992390-97A791E0-4A54-410C-8A8F-DB9EEE1A137CQ34048140-18EA19DE-223F-4A67-B8AE-6D70E9E305F9Q34095945-F6BEF717-A0CC-4E05-A000-2A8313648611Q34095952-3098DCA2-42B2-4D1B-A86F-CCD0EA8A0C3FQ34096234-10904EC9-5C1F-4E6B-B611-D97F807BE318Q34133476-B1F77E6C-A08F-4086-B690-6DB361E14238Q34143769-BB273324-C335-4A01-B36B-9385B5693B3AQ34192940-9D0A5CBF-D049-4A84-A58E-304987626438Q34216817-990AAFE6-8982-47EA-84FA-A12A3D949263
P2860
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Crosstalk between the estrogen ...... endocrine therapy resistance.
@en
type
label
Crosstalk between the estrogen ...... endocrine therapy resistance.
@en
prefLabel
Crosstalk between the estrogen ...... endocrine therapy resistance.
@en
P2093
P2860
P356
P1433
P1476
Crosstalk between the estrogen ...... endocrine therapy resistance.
@en
P2093
C Kent Osborne
Grazia Arpino
Lisa Wiechmann
Rachel Schiff
P2860
P304
P356
10.1210/ER.2006-0045
P577
2008-01-23T00:00:00Z